Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652435 | 0.91 | HPGD (0.42) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2652926 | 0.86 | FGFR1 (0.49) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653042 | 0.85 | FGFR1 (0.42) | HPGDFGFR1SRCKITFLT3 | |
| SCHEMBL4704313 | 0.80 | FGFR1 (0.48) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2653961 | 0.80 | FGFR1 (0.57) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2649765 | 0.79 | HPGD (0.51) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2650302 | 0.79 | HPGD (0.50) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2654310 | 0.79 | FGFR1 (0.52) | HPGDFGFR1ALDH1A1NPC1GLA | |
| SCHEMBL2652290 | 0.78 | FGFR1 (0.46) | HPGDFGFR1SRCALDH1A1NPC1 | |
| SCHEMBL2655791 | 0.78 | ALDH1A1 (0.48) | HPGDFGFR1ALDH1A1NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615896-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2008-04-23 | — | — | EP | claimed |
| US-20060241101-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUSEARCH A/S (DK) | 2006-10-26 | — | — | US | claimed |
| EP-1615896-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089912-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| EP-1615896-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2008-04-23 | — | — | EP | disclosed |
| US-20060241101-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUSEARCH A/S (DK) | 2006-10-26 | — | — | US | disclosed |
| EP-1615896-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089912-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241101-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA2, GABRA1, GABRA5 | HPGD 1091/4885FGFR1 2849/4885SRC 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.